Short answer
Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 8.01 (Other Events). Aldeyra plans to appeal FDA’s March 16, 2026 rejection of reproxalap’s dry-eye NDA through a Formal Dispute Resolution Request.
Aldeyra Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Aldeyra plans to appeal FDA’s March 16, 2026 rejection of reproxalap’s dry-eye NDA through a Formal Dispute Resolution Request
- FDRR submission and FDA Office of New Drugs meeting expected in Q4 2026, creating a potential approval-pathway catalyst
- Reproxalap remains commercially unapproved, preserving regulatory and execution risk despite the appeal
- Operational cash runway extended into 2029, reducing near-term financing pressure during the regulatory process
Item 8.01 · Other Events
- Aldeyra plans an FDA dispute resolution request challenging the March 16, 2026 rejection of reproxalap for dry eye disease
- Reproxalap approval remains uncertain, creating a regulatory catalyst and significant binary risk for investors
- Projected operational cash runway extended into 2029, reducing near-term financing pressure
- Outcome depends on FDA discussions, FDRR timing and potential NDA resubmission acceptance
Item EX-99.1 · Exhibit EX-99.1
- Aldeyra plans a Formal Dispute Resolution Request to FDA’s Office of New Drugs after three complete response letters for reproxalap
- OND meeting expected in Q4 2026, but FDRR timing and outcome remain uncertain
- Nine efficacy trials supported the NDA; five achieved all primary endpoints and 9 of 14 endpoints had P<0.05
- FDA’s latest letter cited insufficient totality of evidence without requesting another clinical trial, preserving a potential regulatory path
- $45.1M cash as of June 30, 2026, with company-estimated runway into 2029 supporting FDRR and ADX-2191 development
Item EX-99.2 · Exhibit EX-99.2
- Aldeyra plans an FDA Formal Dispute Resolution Request in Q4 2026 to appeal reproxalap’s March 16, 2026 rejection for dry eye disease
- Regulatory risk remains high: three Complete Response Letters, with the latest citing insufficient totality of evidence rather than requesting another trial
- Reproxalap has nine controlled trials, including five achieving all multiplicity-controlled primary endpoints, supporting Aldeyra’s appeal case
- Cash and equivalents of $45.1M as of June 30, 2026, now support an operational runway extending into 2029
- FDA Office of New Drugs review timing remains uncertain, potentially involving additional information, experts, or an advisory panel
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aldeyra Therapeutics, Inc. 8-K filings
Get the next ALDX 8-K as it lands
Follow ALDX for push alerts, or ask the research agent what this filing means.